| Year |
Citation |
Score |
| 2012 |
Perez RP, Pendyala L, Elakawi Z, Abu-Hadid M. RT-PCR Quantitation of HSP60 mRNA Expression. Methods in Molecular Medicine. 39: 439-47. PMID 21340800 DOI: 10.1385/1-59259-071-3:439 |
0.311 |
|
| 2011 |
Tummala R, Diegelman P, Hector S, Kramer DL, Clark K, Zagst P, Fetterly G, Porter CW, Pendyala L. Combination effects of platinum drugs and N1, N11 diethylnorspermine on spermidine/spermine N1-acetyltransferase, polyamines and growth inhibition in A2780 human ovarian carcinoma cells and their oxaliplatin and cisplatin-resistant variants. Cancer Chemotherapy and Pharmacology. 67: 401-14. PMID 20443003 DOI: 10.1007/S00280-010-1334-9 |
0.748 |
|
| 2010 |
Tummala R, Diegelman P, Fiuza SM, Batista de Carvalho LA, Marques MP, Kramer DL, Clark K, Vujcic S, Porter CW, Pendyala L. Characterization of Pt-, Pd-spermine complexes for their effect on polyamine pathway and cisplatin resistance in A2780 ovarian carcinoma cells. Oncology Reports. 24: 15-24. PMID 20514439 DOI: 10.3892/Or_00000823 |
0.38 |
|
| 2009 |
Khushalani NI, Miecznikowski J, Wang D, Nowak N, Nava H, Nava ME, Tan W, Iyer R, Yang G, Pendyala L. Capecitabine (C), oxaliplatin (OXP), and radiation (RT) in resectable esophagus cancer (EC): A phase II trial with gene expression profiling (GEP). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: e15543. PMID 27962302 DOI: 10.1200/Jco.2009.27.15_Suppl.E15543 |
0.343 |
|
| 2009 |
Fakih MG, Pendyala L, Egorin MJ, Fetterly G, Espinoza-Delgado I, Ross M, Phelan J, Kramer Z, Yirinec B, Diasio R. A phase I clinical trial of vorinostat in combination with sFULV2 in patients with refractory solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 4083. PMID 27961640 DOI: 10.1200/Jco.2009.27.15_Suppl.4083 |
0.346 |
|
| 2009 |
Fakih MG, Pendyala L, Fetterly G, Toth K, Zwiebel JA, Espinoza-Delgado I, Litwin A, Rustum YM, Ross ME, Holleran JL, Egorin MJ. A phase I, pharmacokinetic and pharmacodynamic study on vorinostat in combination with 5-fluorouracil, leucovorin, and oxaliplatin in patients with refractory colorectal cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 15: 3189-95. PMID 19383814 DOI: 10.1158/1078-0432.Ccr-08-2999 |
0.319 |
|
| 2009 |
Tummala R, Wolle D, Barwe SP, Sampson VB, Rajasekaran AK, Pendyala L. Expression of Na,K-ATPase-beta(1) subunit increases uptake and sensitizes carcinoma cells to oxaliplatin. Cancer Chemotherapy and Pharmacology. 64: 1187-94. PMID 19322565 DOI: 10.1007/S00280-009-0985-X |
0.337 |
|
| 2009 |
Javle MM, Yang G, Nwogu CE, Wilding GE, O'Malley L, Vinjamaram S, Schiff MD, Nava HR, LeVea C, Clark KR, Prey JD, Smith PF, Pendyala L. Capecitabine, oxaliplatin and radiotherapy: a phase IB neoadjuvant study for esophageal cancer with gene expression analysis. Cancer Investigation. 27: 193-200. PMID 19235592 DOI: 10.1080/07357900802172093 |
0.345 |
|
| 2008 |
Kowalski D, Pendyala L, Daignan-Fornier B, Howell SB, Huang RY. Dysregulation of purine nucleotide biosynthesis pathways modulates cisplatin cytotoxicity in Saccharomyces cerevisiae. Molecular Pharmacology. 74: 1092-100. PMID 18612078 DOI: 10.1124/Mol.108.048256 |
0.41 |
|
| 2008 |
Fakih MG, Bullarddunn K, Yang GY, Pendyala L, Toth K, Andrews C, Rustum YM, Ross ME, Levea C, Puthillath A, Park YM, Rajput A. Phase II study of weekly intravenous oxaliplatin combined with oral daily capecitabine and radiotherapy with biologic correlates in neoadjuvant treatment of rectal adenocarcinoma. International Journal of Radiation Oncology, Biology, Physics. 72: 650-7. PMID 18565686 DOI: 10.1016/J.Ijrobp.2008.01.020 |
0.351 |
|
| 2008 |
Abu-Hadid M, Wilkes JD, Elakawi Z, Pendyala L, Perez RP. Relationship between heat shock protein 60 (HSP60) mRNA expression and resistance to platinum analogues in human ovarian and bladder carcinoma cell lines. Cancer Letters. 119: 63-70. PMID 18372523 DOI: 10.1016/S0304-3835(97)00255-3 |
0.42 |
|
| 2008 |
Brun YF, Varma R, Hector SM, Pendyala L, Tummala R, Greco WR. Simultaneous modeling of concentration-effect and time-course patterns in gene expression data from microarrays. Cancer Genomics & Proteomics. 5: 43-53. PMID 18359979 |
0.673 |
|
| 2008 |
Fakih MG, Pendyala L, Brady W, Smith PF, Ross ME, Creaven PJ, Badmaev V, Prey JD, Rustum YM. A Phase I and pharmacokinetic study of selenomethionine in combination with a fixed dose of irinotecan in solid tumors. Cancer Chemotherapy and Pharmacology. 62: 499-508. PMID 17989978 DOI: 10.1007/S00280-007-0631-4 |
0.314 |
|
| 2008 |
Hector S, Tummala R, Kisiel ND, Diegelman P, Vujcic S, Clark K, Fakih M, Kramer DL, Porter CW, Pendyala L. Polyamine catabolism in colorectal cancer cells following treatment with oxaliplatin, 5-fluorouracil and N1, N11 diethylnorspermine. Cancer Chemotherapy and Pharmacology. 62: 517-27. PMID 17987291 DOI: 10.1007/S00280-007-0633-2 |
0.691 |
|
| 2007 |
Javle MM, Cao S, Durrani FA, Pendyala L, Lawrence DD, Smith PF, Creaven PJ, Noel DC, Iyer RV, Rustum YM. Celecoxib and mucosal protection: translation from an animal model to a phase I clinical trial of celecoxib, irinotecan, and 5-fluorouracil. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 13: 965-71. PMID 17289892 DOI: 10.1158/1078-0432.Ccr-06-0551 |
0.35 |
|
| 2007 |
Azrak RG, Cao S, Pendyala L, Durrani FA, Fakih M, Combs GF, Prey J, Smith PF, Rustum YM. Efficacy of increasing the therapeutic index of irinotecan, plasma and tissue selenium concentrations is methylselenocysteine dose dependent. Biochemical Pharmacology. 73: 1280-7. PMID 17239826 DOI: 10.1016/J.Bcp.2006.12.020 |
0.36 |
|
| 2007 |
Varma R, Hector S, Greco WR, Clark K, Hawthorn L, Porter C, Pendyala L. Platinum drug effects on the expression of genes in the polyamine pathway: Time-course and concentration-effect analysis based on Affymetrix gene expression profiling of A2780 ovarian carcinoma cells Cancer Chemotherapy and Pharmacology. 59: 711-723. PMID 17021820 DOI: 10.1007/S00280-006-0325-3 |
0.727 |
|
| 2007 |
Hector S, Nava ME, Clark K, Murphy M, Pendyala L. Characterization of a clonal isolate of an oxaliplatin resistant ovarian carcinoma cell line A2780/C10. Cancer Letters. 245: 195-204. PMID 16516375 DOI: 10.1016/J.Canlet.2006.01.007 |
0.734 |
|
| 2007 |
Rustum Y, Pendyala L, Creaven P, Ross M, Brady W, Badmaev V, Prey J, Fakih MG. A phase I dose escalation study of selenomethionine (SLM) in combination with fixed dose irinotecan (Iri) in patients with solid tumors Journal of Clinical Oncology. 25: 2574-2574. DOI: 10.1200/Jco.2007.25.18_Suppl.2574 |
0.323 |
|
| 2006 |
Leichman L, Lawrence D, Leichman CG, Nava H, Nava E, Proulx G, Clark K, Khushalani NI, Berdzik J, Greco W, Smith P, Creaven PJ, Kepner JL, Javle MM, Pendyala L. Expression of genes related to activity of oxaliplatin and 5-fluorouracil in endoscopic biopsies of primary esophageal cancer in patients receiving oxaliplatin, 5-flourouracil and radiation: characterization and exploratory analysis with survival. Journal of Chemotherapy (Florence, Italy). 18: 514-24. PMID 17127229 DOI: 10.1179/Joc.2006.18.5.514 |
0.364 |
|
| 2006 |
Fakih MG, Rajput A, Yang GY, Pendyala L, Toth K, Smith JL, Lawrence DD, Rustum YM. A Phase I study of weekly intravenous oxaliplatin in combination with oral daily capecitabine and radiation therapy in the neoadjuvant treatment of rectal adenocarcinoma. International Journal of Radiation Oncology, Biology, Physics. 65: 1462-70. PMID 16750332 DOI: 10.1016/J.Ijrobp.2006.03.003 |
0.326 |
|
| 2006 |
Minderman H, O'Loughlin KL, Smith PF, Pendyala L, Greco WR, Sweeney KG, Ford LA, Wetzler M, Baer MR. Sequential administration of irinotecan and cytarabine in the treatment of relapsed and refractory acute myeloid leukemia. Cancer Chemotherapy and Pharmacology. 57: 73-83. PMID 16010591 DOI: 10.1007/S00280-005-0017-4 |
0.312 |
|
| 2006 |
Fakih MG, Pendyala L, Toth K, Creaven P, Soehnlein N, Litwin A, Trump D. A phase I study of vorinostat (suberoylanilide hydroxamic acid, SAHA) in combination with 5-fluorouracil, leucovorin, and oxaliplatin (FOLFOX) in patients with advanced colorectal cancer (CRC) Journal of Clinical Oncology. 24: 3592-3592. DOI: 10.1200/Jco.2006.24.18_Suppl.3592 |
0.369 |
|
| 2006 |
Trump D, Javle M, Muindi J, Pendyala L, Yu W, Ramnath N, Ross M, Fakih M, Iyer R, Johnson C. Phase I, pharmacokinetic (PK), pharmacodynamic study of paricalcitol [19-nor-1 alpha, 25-(OH)2 D2] in combination with gemcitabine [2’,2’ difluorodeoxycytidine] in patients with advanced malignancies Journal of Clinical Oncology. 24: 12010-12010. DOI: 10.1200/Jco.2006.24.18_Suppl.12010 |
0.369 |
|
| 2006 |
Pendyala L, Wilding G, Smith P, lyer R, Nava H, Nwogu C, Javle M. 298 POSTER Oxaliplatin induces the expression of genes involved in capecitabine activation: preliminary results of a pharmacodynamic study in esophageal cancer European Journal of Cancer Supplements. 4: 94. DOI: 10.1016/S1359-6349(06)70303-2 |
0.356 |
|
| 2006 |
SMITH P, FAKIH M, PENDYALA L, PREY J, AZRAK R, CREAVEN P, RUSTUM Y. OIV-A-1Pharmacokinetics and dose optimization of selenomethionine (SLM) as an adjunct to irinotecan (CPT-11) therapy Clinical Pharmacology & Therapeutics. 79: P31-P31. DOI: 10.1016/J.Clpt.2005.12.114 |
0.336 |
|
| 2005 |
Rustum Y, Pendyala L, Creaven PJ, Smith P, Azrak R, Cao S, Durrani F, Lawrence DD, Badmaev V, Diane NC, Fakih MG. A phase I and pharmacokinetic (PK) study of high dose selenomethionine (SLM) in combination with irinotecan (IRI) in patients with advanced solid tumors. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 2080. PMID 27946928 DOI: 10.1200/Jco.2005.23.16_Suppl.2080 |
0.324 |
|
| 2005 |
Creaven PJ, Javle MM, Pendyala L, Smith P, Noel DC, Iyer RV, Lawrence DD, Rustum YM. Celecoxib in combination with irinotecan (CPT-11), 5-fluorouracil and leucovorin in patients with advanced cancer: A phase I, pharmacokinetic study. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 2092. PMID 27946658 DOI: 10.1200/Jco.2005.23.16_Suppl.2092 |
0.356 |
|
| 2005 |
Fakih MG, Rajput A, Yang GY, Pendyala L, Toth K, Lawrence DD, Smith JL, Soehnlein NA, Flaherty L, Rustum YM. A phase I and biological correlates study of capecitabine (CAP) + oxaliplatin (OX) + radiation therapy (RT) in locally advanced rectal cancer (LARC). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 23: 3633. PMID 27944848 DOI: 10.1200/Jco.2005.23.16_Suppl.3633 |
0.308 |
|
| 2005 |
Varma RR, Hector SM, Clark K, Greco WR, Hawthorn L, Pendyala L. Gene expression profiling of a clonal isolate of oxaliplatin-resistant ovarian carcinoma cell line A2780/C10. Oncology Reports. 14: 925-32. PMID 16142353 DOI: 10.3892/Or.14.4.925 |
0.734 |
|
| 2005 |
Minderman H, Conroy JM, O'Loughlin KL, McQuaid D, Quinn P, Li S, Pendyala L, Nowak NJ, Baer MR. In vitro and in vivo irinotecan-induced changes in expression profiles of cell cycle and apoptosis-associated genes in acute myeloid leukemia cells. Molecular Cancer Therapeutics. 4: 885-900. PMID 15956246 DOI: 10.1158/1535-7163.Mct-04-0048 |
0.384 |
|
| 2005 |
Ramnath N, Khushalani N, Toth K, Litwin AM, Intengan ME, Slocum HK, Pendyala L, Smith PF, Stewart CC, Hoffman JL, Javle MM, Berdzik J, Creaven PJ, Rustum YM. S-phase modulation by irinotecan: pilot studies in advanced solid tumors. Cancer Chemotherapy and Pharmacology. 56: 447-54. PMID 15947933 DOI: 10.1007/S00280-004-0951-6 |
0.316 |
|
| 2005 |
Azrak RG, Yu J, Pendyala L, Smith PF, Cao S, Li X, Shannon WD, Durrani FA, McLeod HL, Rustum YM. Irinotecan pharmacokinetic and pharmacogenomic alterations induced by methylselenocysteine in human head and neck xenograft tumors. Molecular Cancer Therapeutics. 4: 843-54. PMID 15897249 DOI: 10.1158/1535-7163.Mct-04-0315 |
0.421 |
|
| 2004 |
Leichman LP, Lawrence D, Clark K, Nava H, Nava E, Leichman CG, Proulx G, Berdzik J, Greco W, Pendyala L. Updated results of an exploratory gene expression analysis for primary esophageal cancer (PEC) patients (pts) treated with oxaliplatin (OXP), protracted infusion (PI) 5FU and radiation (XRT). Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 22: 4014. PMID 28016452 DOI: 10.1200/Jco.2004.22.14_Suppl.4014 |
0.325 |
|
| 2004 |
Bhattacharya A, Tóth K, Mazurchuk R, Spernyak JA, Slocum HK, Pendyala L, Azrak R, Cao S, Durrani FA, Rustum YM. Lack of microvessels in well-differentiated regions of human head and neck squamous cell carcinoma A253 associated with functional magnetic resonance imaging detectable hypoxia, limited drug delivery, and resistance to irinotecan therapy. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 8005-17. PMID 15585636 DOI: 10.1158/1078-0432.Ccr-04-1306 |
0.364 |
|
| 2004 |
Bassett E, King NM, Bryant MF, Hector S, Pendyala L, Chaney SG, Cordeiro-Stone M. The role of DNA polymerase eta in translesion synthesis past platinum-DNA adducts in human fibroblasts. Cancer Research. 64: 6469-75. PMID 15374956 DOI: 10.1158/0008-5472.Can-04-1328 |
0.726 |
|
| 2004 |
Hector S, Porter CW, Kramer DL, Clark K, Prey J, Kisiel N, Diegelman P, Chen Y, Pendyala L. Polyamine catabolism in platinum drug action: Interactions between oxaliplatin and the polyamine analogue N1,N11-diethylnorspermine at the level of spermidine/spermine N1-acetyltransferase. Molecular Cancer Therapeutics. 3: 813-22. PMID 15252142 |
0.73 |
|
| 2004 |
Minderman H, O'Loughlin KL, Pendyala L, Baer MR. VX-710 (biricodar) increases drug retention and enhances chemosensitivity in resistant cells overexpressing P-glycoprotein, multidrug resistance protein, and breast cancer resistance protein. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 1826-34. PMID 15014037 DOI: 10.1158/1078-0432.Ccr-0914-3 |
0.341 |
|
| 2004 |
Azrak RG, Cao S, Slocum HK, Tóth K, Durrani FA, Yin MB, Pendyala L, Zhang W, McLeod HL, Rustum YM. Therapeutic synergy between irinotecan and 5-fluorouracil against human tumor xenografts. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 10: 1121-9. PMID 14871992 DOI: 10.1158/1078-0432.Ccr-0913-3 |
0.317 |
|
| 2003 |
Smith PF, Booker BM, Creaven P, Perez R, Pendyala L. Pharmacokinetics and pharmacodynamics of mesna-mediated plasma cysteine depletion. Journal of Clinical Pharmacology. 43: 1324-8. PMID 14615468 DOI: 10.1177/0091270003260332 |
0.328 |
|
| 2003 |
Leichman L, Pendyala L, Leichman CG. Definitive and neoadjuvant therapies for esophageal and gastroesophageal junction tumors: a look back and toward the future. Seminars in Oncology. 30: 11-8. PMID 14506599 DOI: 10.1016/S0093-7754(03)00297-5 |
0.317 |
|
| 2003 |
Pendyala L, Schwartz G, Smith P, Zdanowicz J, Murphy M, Hausheer F. Modulation of plasma thiols and mixed disulfides by BNP7787 in patients receiving paclitaxel/cisplatin therapy. Cancer Chemotherapy and Pharmacology. 51: 376-84. PMID 12682786 DOI: 10.1007/S00280-003-0587-Y |
0.32 |
|
| 2002 |
Khushalani NI, Leichman CG, Proulx G, Nava H, Bodnar L, Klippenstein D, Litwin A, Smith J, Nava E, Pendyala L, Smith P, Greco W, Berdzik J, Douglass H, Leichman L. Oxaliplatin in combination with protracted-infusion fluorouracil and radiation: report of a clinical trial for patients with esophageal cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 20: 2844-50. PMID 12065561 DOI: 10.1200/Jco.2002.12.032 |
0.315 |
|
| 2001 |
Hector S, Bolanowska-Higdon W, Zdanowicz J, Hitt S, Pendyala L. In vitro studies on the mechanisms of oxaliplatin resistance. Cancer Chemotherapy and Pharmacology. 48: 398-406. PMID 11761458 DOI: 10.1007/S002800100363 |
0.739 |
|
| 1999 |
Schwartz GN, Pendyala L, Kindler H, Meropol N, Perez R, Raghavan D, Creaven P. The clinical development of paclitaxel and the paclitaxel/carboplatin combination. European Journal of Cancer (Oxford, England : 1990). 34: 1543-8. PMID 9893625 DOI: 10.1016/S0959-8049(98)00225-1 |
0.348 |
|
| 1998 |
Creaven PJ, Perez R, Pendyala L, Meropol NJ, Loewen G, Levine E, Berghorn E, Raghavan D. Unusual central nervous system toxicity in a phase I study of N1N11 diethylnorspermine in patients with advanced malignancy. Investigational New Drugs. 15: 227-34. PMID 9387045 DOI: 10.1023/A:1005827231849 |
0.323 |
|
| 1997 |
Pendyala L, Perez R, Weinstein A, Zdanowicz J, Creaven PJ. Effect of glutathione depletion on the cytotoxicity of cisplatin and iproplatin in a human melanoma cell line. Cancer Chemotherapy and Pharmacology. 40: 38-44. PMID 9137527 DOI: 10.1007/S002800050622 |
0.397 |
|
| 1997 |
Soni N, Meropol NJ, Pendyala L, Noel D, Schacter LP, Gunton KE, Creaven PJ. Phase I and pharmacokinetic study of etoposide phosphate by protracted venous infusion in patients with advanced cancer. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 15: 766-72. PMID 9053503 DOI: 10.1200/Jco.1997.15.2.766 |
0.342 |
|
| 1996 |
El-Akawi Z, Abu-Hadid M, Perez R, Glavy J, Zdanowicz J, Creaven PJ, Pendyala L. Altered glutathione metabolism in oxaliplatin resistant ovarian carcinoma cells Cancer Letters. 105: 5-14. PMID 8689632 DOI: 10.1016/0304-3835(96)04245-0 |
0.427 |
|
| 1996 |
Pendyala L, Kidani Y, Perez R, Wilkes J, Bernacki RJ, Creaven PJ. Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers. Cancer Letters. 97: 177-84. PMID 7497460 DOI: 10.1016/0304-3835(95)03974-2 |
0.347 |
|
| 1995 |
Pendyala L, Creaven PJ, Perez R, Zdanowicz JR, Raghavan D. Intracellular glutathione and cytotoxicity of platinum complexes. Cancer Chemotherapy and Pharmacology. 36: 271-8. PMID 7628045 DOI: 10.1007/Bf00689042 |
0.378 |
|
| Show low-probability matches. |